Interview with Braizon Therapeutics

Applying intelligently glycemic control and a systematic route through the BBB (blood-brain barrier) to effectively reach neurons. Venture Valuation (VV) interviewed the CEO, Mariko Tosu, PhD

Read more

Whitepaper: Life Sciences – 409A valuation vs. valuation to raise money

The US Internal Revenue Code has numerous regulations which must be adhered to in order for companies to reach compliance standards. One such regulation, Section 409A of the IRC, governs the complexities of setting strike prices for employee stock options and requires that companies be properly audited before issuing stock options as employee compensation. Often … Continue reading Whitepaper: Life Sciences – 409A valuation vs. valuation to raise money

Read more

Biotechgate announces the launch of a clinical trial database

Zurich, 25th March 2019 Biotechgate announces the launch of a clinical trial database with more than 460,000 trial records. Clinical trial data is imported from more than 13 registries around the world and continuously updated and catalogued. Thanks to the use of newly developed smart software components, the data is presented in a well-structured and … Continue reading Biotechgate announces the launch of a clinical trial database

Read more

Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals

Switzerland, March 2019: Venture Valuation has been working with Ferring Pharmaceutical supporting the company with external, third-party product/asset valuations of potential in-licensing opportunities. After Ferring had identified a specific opportunity and deemed interesting to move it forward in the internal evaluation process, Venture Valuation was mandated to review the product/opportunity from an external point of … Continue reading Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals

Read more

Interviews with leading Life Sciences companies: Ava AG

Inspired by co-founder Lea von Bidder’s concept, the Ava bracelet is becoming an indispensable device for women to monitor their own biological rhythms. Venture Valuation (VV) interviewed Vicky Kummer, Global Brand Manager. Read the interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

Read more

Biotechgate, HEALTH MADE IN GERMANY and Germany Trade & Invest (GTAI) to map German Life Science Industry

Zurich/Berlin, January 2019; Venture Valuation entered into a partnership with HEALTH MADE IN GERMANY, the export promotion program for the German healthcare industry initiated by the German Federal Ministry for Economic Affairs and Energy. HEALTH MADE IN GERMANY is implemented by Germany Trade & Invest (GTAI), the country’s economic development agency.  It is Venture Valuation’s … Continue reading Biotechgate, HEALTH MADE IN GERMANY and Germany Trade & Invest (GTAI) to map German Life Science Industry

Read more

J.P. Morgan Healthcare Conference Round-up by Venture Valuation / Biotechgate

14 January 2019. Last week saw the annual J.P. Morgan Healthcare Conference held in San Francisco. Venture Valuation and Biotechgate was represented by CEO, Patrik Frei and Senior Business Development Executive Ray Carroll providing their insights into the industry announcements. It was again a busy week in San Francisco kicking off the Bio year 2019 … Continue reading J.P. Morgan Healthcare Conference Round-up by Venture Valuation / Biotechgate

Read more